$17.04
2.02% today
Nasdaq, Apr 03, 06:46 pm CET
ISIN
US8902604094
Symbol
TNXP
Sector
Industry

Tonix Pharmaceuticals Holding Corp. Stock price

$17.39
+10.01 135.64% 1M
+4.34 33.26% 6M
-15.59 47.27% YTD
-592.53 97.15% 1Y
-146,350.61 99.99% 3Y
-435,118.61 100.00% 5Y
-3,884,799,982.61 100.00% 10Y
Nasdaq, Closing price Wed, Apr 02 2025
-0.06 0.34%
ISIN
US8902604094
Symbol
TNXP
Sector
Industry

Key metrics

Market capitalization $111.90m
Enterprise Value $21.24m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 2.11
P/S ratio (TTM) P/S ratio 11.09
P/B ratio (TTM) P/B ratio 0.55
Revenue growth (TTM) Revenue growth 29.94%
Revenue (TTM) Revenue $10.09m
EBIT (operating result TTM) EBIT $-77.74m
Free Cash Flow (TTM) Free Cash Flow $-61.27m
Cash position $98.78m
EPS (TTM) EPS $-29.46
P/S forward 10.08
EV/Sales forward 1.91
Short interest 9.86%
Show more

Is Tonix Pharmaceuticals Holding Corp. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Tonix Pharmaceuticals Holding Corp. Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Tonix Pharmaceuticals Holding Corp.:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Tonix Pharmaceuticals Holding Corp.:

Buy
100%

Financial data from Tonix Pharmaceuticals Holding Corp.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
10 10
30% 30%
100%
- Direct Costs 11 11
24% 24%
111%
-1.08 -1.08
12% 12%
-11%
- Selling and Administrative Expenses 33 33
27% 27%
330%
- Research and Development Expense 40 40
54% 54%
396%
-74 -74
35% 35%
-737%
- Depreciation and Amortization 3.41 3.41
20% 20%
34%
EBIT (Operating Income) EBIT -78 -78
34% 34%
-771%
Net Profit -130 -130
11% 11%
-1,289%

In millions USD.

Don't miss a Thing! We will send you all news about Tonix Pharmaceuticals Holding Corp. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Tonix Pharmaceuticals Holding Corp. Stock News

Neutral
GlobeNewsWire
one day ago
CHATHAM, N.J., April 02, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that Seth Lederman M.D.
Neutral
GlobeNewsWire
2 days ago
CHATHAM, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a biopharmaceutical company with a portfolio of marketed products and a pipeline of development candidates, today announced the launch of TONIX ONE™, a fully-integrated digital platform designed to help patients better understand and manage their migraine condition.
Neutral
Accesswire
3 days ago
CHATHAM, NJ / ACCESS Newswire / March 31, 2025 / This post was written and published as a collaboration between the in-house editorial team at Benzinga and Tonix Pharmaceuticals Holding Corp. with financial support from Tonix. The two organizations work to ensure that any and all information contained within is true and accurate as of the date hereof to the best of their knowledge and research.
More Tonix Pharmaceuticals Holding Corp. News

Company Profile

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company. It focuses on discovering and developing small molecules and biologics to treat psychiatric, pain and addiction conditions, to improve biodefense through potential medical counter-measures, to treat transplant rejection and to treat gastric and pancreatic cancers. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and Tonmya. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in New York, NY.

Head office United States
CEO Seth Lederman
Employees 81
Founded 2007
Website www.tonixpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today